Canopy Growth (CGC)
(Delayed Data from NSDQ)
$4.41 USD
-0.41 (-8.51%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $4.42 +0.01 (0.23%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.41 USD
-0.41 (-8.51%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $4.42 +0.01 (0.23%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Zacks News
Cardiovascular Systems (CSII) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cardiovascular Systems (CSII) delivered earnings and revenue surprises of -12.50% and 0.58%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Nephros Inc. (NEPH) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Nephros Inc. (NEPH) delivered earnings and revenue surprises of 0% and 4.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for September 30th
by Zacks Equity Research
CGC, ESALY and META have been added to the Zacks Rank #5 (Strong Sell) List on September 30, 2022.
Canopy Growth Corporation (CGC) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Canopy Growth Corporation (CGC) delivered earnings and revenue surprises of -250% and 0.02%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Canopy Growth (CGC) This Earnings Season?
by Zacks Equity Research
Canopy Growth (CGC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -58.33% and 0.90%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Canopy Growth Corporation (CGC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Canopy Growth Corporation (CGC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Canopy Growth Corporation (CGC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed at $2.54 in the latest trading session, marking a -0.97% move from the prior day.
Canopy Growth Corporation (CGC) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed at $2.61 in the latest trading session, marking a +0.77% move from the prior day.
Canopy Growth Corporation (CGC) Stock Moves -0.87%: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed the most recent trading day at $2.29, moving -0.87% from the previous trading session.
Canopy Growth Corporation (CGC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Canopy Growth Corporation (CGC) closed at $2.81, marking a -1.4% move from the previous day.
Company News for May 31, 2022
by Zacks Equity Research
Companies in The News Are: PDD, CGC, COST, ULTA
Canopy Growth Corporation (CGC) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Canopy Growth Corporation (CGC) delivered earnings and revenue surprises of -75% and 14.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Canopy Growth (CGC) Might Surprise This Earnings Season
by Zacks Equity Research
Canopy Growth (CGC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Medtronic (MDT) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Medtronic (MDT) delivered earnings and revenue surprises of -2.56% and 3.85%, respectively, for the quarter ended April 2022. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Canopy Growth (CGC) in Q4 Earnings?
by Zacks Equity Research
Product launches across the CBD product portfolio and robust demand for legal cannabis products are likely to have driven Canopy Growth's (CGC) Q4 top line.
Canopy Growth Corporation (CGC) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Canopy Growth Corporation (CGC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Think Canopy Growth Corporation (CGC) Could Surge 55%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Canopy Growth Corporation (CGC) points to a 54.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Homology Medicines (FIXX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Homology Medicines (FIXX) delivered earnings and revenue surprises of 20% and 38.31%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Apyx Medical (APYX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Apyx (APYX) delivered earnings and revenue surprises of -30.77% and 7.70%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Canopy Growth Corporation (CGC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed the most recent trading day at $5.44, moving -1.98% from the previous trading session.
3 Medical Product Stocks Set to Beat on Earnings This Season
by Trina Mukherjee
Medical product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how CGC, HAE and ALC are poised ahead of their earnings releases.
Canopy Growth Corporation (CGC) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed at $6.06 in the latest trading session, marking a +0.17% move from the prior day.
Canopy Growth Corporation (CGC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Canopy Growth Corporation (CGC) closed at $5.23, marking a -1.32% move from the previous day.
Canopy Growth Corporation (CGC) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed at $5.75 in the latest trading session, marking a +0.35% move from the prior day.